Search clinical trials for: BI 207127 NA

Total 1504 results

Boehringer Ingelheim

Completed

Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 207127 NA in Healthy Male Asian Volunteers and Single Dose Study of BI 207127 NA in Healthy Male Caucasian Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

Single Rising Oral Doses of BI 207127 NA as Powder in the Bottle in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male Volunteers

Healthy

United States
Boehringer Ingelheim

Completed

Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients

Hepatitis C, Chronic
Boehringer Ingelheim

Completed

This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Japan
Boehringer Ingelheim

Completed

Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection

Hepatitis C, Chronic

United States, Australia, Austria, France, Germany, New Zealand, Portugal, Romania, Spain, Switzerland
Boehringer Ingelheim

Completed

Bioavailability of 3 Different Formulations of BI 207127 in Healthy Male Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients

Hepatitis C, Chronic

France, Germany, Switzerland
Boehringer Ingelheim

Terminated

Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Renal Impaired Patients

Renal Insufficiency

Germany
Boehringer Ingelheim

Terminated

Effect of Food and Increased Gastric pH Value on Bioavailability of a Single Dose of BI 207127 in Healthy Caucasian and Japanese Subjects

Healthy

Germany
Presidio Pharmaceuticals, Inc.
Boehringer Ingelheim

Completed

Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C

Chronic Hepatitis C

United States
Boehringer Ingelheim

Completed

Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules

Hepatitis C

Japan
Boehringer Ingelheim

Completed

Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)

Hepatitis C, Chronic

United States, Argentina, Australia, Austria, Canada, Czech Republic, France, Germany, Korea, Republic of, Netherlands, Portugal, Romania, Spain, Switzerland, United Kingdom
Boehringer Ingelheim

Completed

BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

Hepatitis C, Chronic

United States, Germany, Spain, United Kingdom
Boehringer Ingelheim

Completed

Bioavailability of Soft Gelatin Capsule Formulation of BI 201335 NA Compared to the Solution Formulation in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of Oral Solution of [14C]-BI 201335 in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients

Hepatitis C | Pharmacokinetics

Japan
Boehringer Ingelheim

Terminated

Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, and Pharmacokinetics of BI 201335 NA in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 201335 NA in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

Hepatitis C, Chronic

United States, Australia, Belgium, Canada, France, Germany, Greece, Italy, New Zealand, Portugal, Spain, United Kingdom
Boehringer Ingelheim

Completed

Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of BI 201335 NA and Bioavailability in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1

Hepatitis C, Chronic

United States, Austria, Canada, France, Germany, Hungary, Ireland, Italy, Netherlands, Portugal, Romania, Russian Federation, Spain, United Kingdom
Boehringer Ingelheim

Completed

Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Subjects.

Healthy

Germany
Boehringer Ingelheim

Withdrawn

Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients

Hepatitis C, Chronic

Australia, Spain, Sweden
STEBA France
STEBA LABORATORIES LTD.

Completed

Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers

Gastroesophageal Reflux | Esophagitis | Duodenal Ulcer | Stomach Ulcer

United States
University Health Network, Toronto

Unknown

Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues (Stop)

Chronic Hepatitis B

Canada
Asahi Kasei Pharma Corporation

Recruiting

Value of Glycated Albumin in Intervention of Glycemic Control in Chinese Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

China
Purdue University
Johns Hopkins University; University of California, San Diego; National Heart... and other collaborators

Terminated

DASH-Sodium Trial in Adolescents (CampDASH)

Blood High Pressure

United States
University College, London

Active, not recruiting

Exploiting Risk-Based Risk Stratification in Early Prostate Cancer to Discriminate Progressors From Non-Progressors (RECONCILE)

Prostate Cancer

United Kingdom
HaEmek Medical Center, Israel
Technion, Israel Institute of Technology

Unknown

Detection of Placenta Accreta Via Exhaled Women Breath

Placenta Accreta, Third Trimester

Israel
University of Manitoba

Unknown

Identifying a Sleep Screener for Disease Relapse in Children With Inflammatory Bowel Disease

IBD

Canada
STEBA France

Suspended

Efficiency Study of S-Tenatoprazole-Na to Treat Erosive or Ulcerative Esophagitis

Esophagitis, Reflux

Canada
Addpharma Inc.

Completed

Evaluating the Pharmacokinetic Interaction Between AD-2071 and AD-2072

Hypertension | Hyperlipidemias

Korea, Republic of
Kresge Eye Institute

Suspended

Fluorescein Angiography With a Full-dose Versus a Half-dose of Intravenous Fluorescein

Fluorescein Angiography

United States
Changi General Hospital
National Taiwan University Hospital; Asan Medical Center

Completed

RCT: Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses

Pancreatic Diseases | Pancreatic Neoplasm

Singapore
NoNO Inc.
University of Calgary

Completed

Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke (ESCAPE-NA1)

Stroke, Acute

United States, Ireland, Korea, Republic of, Canada, Sweden, Germany, United Kingdom, Australia
Austin Health

Completed

Endoscopy-related Phone Consultation During the COVID-19 Outbreak

Reflux, Gastroesophageal | Colon Disease | Colon Polyp | Varices, Esophageal

Australia
University Medical Center Groningen

Completed

The Identification of Phenotypes in Patients With Severe Chronic Obstructive Pulmonary Disease (Groningen Severe COPD Cohort)

Severe COPD
Wageningen University
Nexira; Roquette Freres; Netherlands: Ministry of Health, Welfare and Sports; B... and other collaborators

Completed

Microbiota Profiling in IBS (IBSQUtrition)

Irritable Bowel Syndrome | Microbial Colonization | Dietary Habits

Netherlands
University Hospital, Geneva
University of Geneva, Switzerland

Completed

Understanding COVID-19

SARS-CoV-2 Viral Kinetics and Host Immune Responses

Switzerland
King Khalid University

Unknown

Effect of Covid-19 Affliction on Psychological and Mental Health Among College Going Students: Cross-Sectional Survey

Covid19

Saudi Arabia
Children's Hospital of Philadelphia

Completed

Characterization of Cleft Lip and Palate Conditions in Guatemala

Cleft Lip and Palate | Cleft Palate | Cleft Lip

United States
The University of Hong Kong
Yan Chai Hospital

Completed

A Study on Effects of Acupressure Among the Frail Elderly in the Community Dwellings

Impaired

China
Samsung Medical Center

Not yet recruiting

Genomic Profiling of Pancreatic Cystic Tumors

Pancreatic Cyst

Korea, Republic of
National Taiwan University Hospital
National Taiwan University Hospital Hsin-Chu Branch; National Taiwan University...

Recruiting

Cardiac Amyloidosis in HFpEF

Heart Failure With Preserved Ejection Fraction | Amyloidosis Cardiac

Taiwan
The University of Hong Kong
Yan Chai Hospital

Completed

A Study on Effects of Acupressure Among the Frail Elderly in Residential Care Services for the Elderly

Impaired

China
NoNO Inc.

Withdrawn

Safety and Efficacy Study of a Single Dose of NA-1 in Patients Undergoing Endovascular Repair of Ruptured Aneurysms (ENACT-2)

Subarachnoid Hemorrhage | Ruptured Intracranial Aneurysm

Canada, United States

3

Subscribe